Greystone Financial Group, LLC Abb Vie Inc. Transaction History

Greystone Financial Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$137.62 - $174.96 $4.81 Million - $6.12 Million	-34,951 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$131.98 - $163.75 $6.25 Million - $7.75 Million	-47,357 Reduced 57.54%	34,951 $5.67 Million
Q4 2021 Feb 01, 2022	BUY	$107.43 - $135.93 $1.66 Million - $2.1 Million	15,419 Added 23.05%	82,308 $11.1 Million
Q3 2021 Nov 03, 2021	SELL	$106.4 - $120.78 $1.05 Million - $1.2 Million	-9,899 Reduced 12.89%	66,889 $7.22 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $73,226 - $81,578	696 Added 0.91%	76,788 $8.65 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $151,608 - $166,902	1,482 Added 1.99%	76,092 $8.74 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $6.01 Million - $8.11 Million	74,610 New	74,610 $7.97 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Greystone Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Greystone Financial Group, LLC with notifications on news.